1
|
Plewe MB, Gantla VR, Sokolova NV, Shin YJ, Naik S, Brown ER, Fetsko A, Zhang L, Kalveram B, Freiberg AN, Henkel G, McCormack K. Discovery of a novel highly potent broad-spectrum heterocyclic chemical series of arenavirus cell entry inhibitors. Bioorg Med Chem Lett 2021; 41:127983. [PMID: 33965007 PMCID: PMC10187606 DOI: 10.1016/j.bmcl.2021.127983] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Revised: 03/12/2021] [Accepted: 03/14/2021] [Indexed: 12/25/2022]
Abstract
We identified and explored the structure-activity relationship (SAR) of a novel heterocyclic chemical series of arenavirus cell entry inhibitors. Optimized lead compounds, including diphenyl-substituted imidazo[1,2-a]pyridines, benzimidazoles, and benzotriazoles exhibited low to sub-nanomolar potency against both pseudotyped and infectious Old and New World arenaviruses, attractive metabolic stability in human and most nonhuman liver microsomes as well as a lack of hERG K + channel or CYP enzyme inhibition. Moreover, the straightforward synthesis of several lead compounds (e.g., the simple high yield 3-step synthesis of imidazo[1,2-a]pyridine 37) could provide a cost-effective broad-spectrum arenavirus therapeutic that may help to minimize the cost-prohibitive burdens associated with treatments for emerging viruses in economically challenged geographical settings.
Collapse
Affiliation(s)
- Michael B Plewe
- Arisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego 92121, CA, United States
| | - Vidyasagar Reddy Gantla
- Arisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego 92121, CA, United States
| | - Nadezda V Sokolova
- Arisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego 92121, CA, United States
| | - Young-Jun Shin
- Arisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego 92121, CA, United States
| | - Shibani Naik
- Arisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego 92121, CA, United States
| | - Eric R Brown
- Arisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego 92121, CA, United States
| | - Alexandra Fetsko
- Arisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego 92121, CA, United States
| | - Lihong Zhang
- Department of Pathology, and Center for Biodefense and Emerging Infectious Diseases, The University of Texas Medical Branch, Galveston 77555, TX, United States
| | - Birte Kalveram
- Department of Pathology, and Center for Biodefense and Emerging Infectious Diseases, The University of Texas Medical Branch, Galveston 77555, TX, United States
| | - Alexander N Freiberg
- Department of Pathology, and Center for Biodefense and Emerging Infectious Diseases, The University of Texas Medical Branch, Galveston 77555, TX, United States
| | - Greg Henkel
- Arisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego 92121, CA, United States
| | - Ken McCormack
- Arisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego 92121, CA, United States.
| |
Collapse
|
2
|
Plewe MB, Sokolova NV, Gantla VR, Brown ER, Naik S, Fetsko A, Lorimer DD, Dranow DM, Smutney H, Bullen J, Sidhu R, Master A, Wang J, Kallel EA, Zhang L, Kalveram B, Freiberg AN, Henkel G, McCormack K. Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors. ACS Med Chem Lett 2020; 11:1160-1167. [PMID: 32550996 DOI: 10.1021/acsmedchemlett.0c00025] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Accepted: 04/21/2020] [Indexed: 12/24/2022] Open
Abstract
We identified and explored the structure-activity-relationship (SAR) of an adamantane carboxamide chemical series of Ebola virus (EBOV) inhibitors. Selected analogs exhibited half-maximal inhibitory concentrations (EC50 values) of ∼10-15 nM in vesicular stomatitis virus (VSV) pseudotyped EBOV (pEBOV) infectivity assays, low hundred nanomolar EC50 activity against wild type EBOV, aqueous solubility >20 mg/mL, and attractive metabolic stability in human and nonhuman liver microsomes. X-ray cocrystallographic characterizations of a lead compound with the EBOV glycoprotein (GP) established the EBOV GP as a target for direct compound inhibitory activity and further provided relevant structural models that may assist in identifying optimized therapeutic candidates.
Collapse
Affiliation(s)
- Michael B. Plewe
- Arisan Therapeutics, 11189 Sorrento Valley Road, Suite 104, San Diego, California 92121, United States
| | - Nadezda V. Sokolova
- Arisan Therapeutics, 11189 Sorrento Valley Road, Suite 104, San Diego, California 92121, United States
| | - Vidyasagar Reddy Gantla
- Arisan Therapeutics, 11189 Sorrento Valley Road, Suite 104, San Diego, California 92121, United States
| | - Eric R. Brown
- Arisan Therapeutics, 11189 Sorrento Valley Road, Suite 104, San Diego, California 92121, United States
| | - Shibani Naik
- Arisan Therapeutics, 11189 Sorrento Valley Road, Suite 104, San Diego, California 92121, United States
| | - Alexandra Fetsko
- Arisan Therapeutics, 11189 Sorrento Valley Road, Suite 104, San Diego, California 92121, United States
| | - Donald D. Lorimer
- Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, Washington 98105, United States
- UCB Pharma, 7869 NE Day Road West, Bainbridge Island, Washington 98110, United States
| | - David M. Dranow
- Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, Washington 98105, United States
- UCB Pharma, 7869 NE Day Road West, Bainbridge Island, Washington 98110, United States
| | - Hayden Smutney
- Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, Washington 98105, United States
- UCB Pharma, 3 Preston Court, Bedford, Massachusetts 01730, United States
| | - Jameson Bullen
- Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, Washington 98105, United States
- UCB Pharma, 7869 NE Day Road West, Bainbridge Island, Washington 98110, United States
| | - Rana Sidhu
- Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, Washington 98105, United States
- UCB Pharma, 3 Preston Court, Bedford, Massachusetts 01730, United States
| | - Arshil Master
- Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, Washington 98105, United States
- UCB Pharma, 3 Preston Court, Bedford, Massachusetts 01730, United States
| | - Junru Wang
- Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, Washington 98105, United States
- UCB Pharma, 3 Preston Court, Bedford, Massachusetts 01730, United States
| | - E. Adam Kallel
- Victrix, 12631 Bendito Drive, San Diego, California 92128, United States
| | | | | | | | - Greg Henkel
- Arisan Therapeutics, 11189 Sorrento Valley Road, Suite 104, San Diego, California 92121, United States
| | - Ken McCormack
- Arisan Therapeutics, 11189 Sorrento Valley Road, Suite 104, San Diego, California 92121, United States
| |
Collapse
|
3
|
Plewe MB, Whitby LR, Naik S, Brown ER, Sokolova NV, Gantla VR, York J, Nunberg JH, Zhang L, Kalveram B, Freiberg AN, Boger DL, Henkel G, McCormack K. SAR studies of 4-acyl-1,6-dialkylpiperazin-2-one arenavirus cell entry inhibitors. Bioorg Med Chem Lett 2019; 29:126620. [PMID: 31537423 PMCID: PMC6803051 DOI: 10.1016/j.bmcl.2019.08.024] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2019] [Revised: 08/10/2019] [Accepted: 08/11/2019] [Indexed: 12/13/2022]
Abstract
Old World (Africa) and New World (South America) arenaviruses are associated with human hemorrhagic fevers. Efforts to develop small molecule therapeutics have yielded several chemical series including the 4-acyl-1,6-dialkylpiperazin-2-ones. Herein, we describe an extensive exploration of this chemotype. In initial Phase I studies, R1 and R4 scanning libraries were assayed to identify potent substituents against Old World (Lassa) virus. In subsequent Phase II studies, R6 substituents and iterative R1, R4 and R6 substituent combinations were evaluated to obtain compounds with improved Lassa and New World (Machupo, Junin, and Tacaribe) arenavirus inhibitory activity, in vitro human liver microsome metabolic stability and aqueous solubility.
Collapse
Affiliation(s)
- Michael B Plewe
- Arisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego, CA 92054, United States
| | - Landon R Whitby
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, United States
| | - Shibani Naik
- Arisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego, CA 92054, United States
| | - Eric R Brown
- Arisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego, CA 92054, United States
| | - Nadezda V Sokolova
- Arisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego, CA 92054, United States
| | - Vidyasagar Reddy Gantla
- Arisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego, CA 92054, United States
| | - Joanne York
- Montana Biotechnology Center, The University of Montana, Missoula, MT 59812, United States
| | - Jack H Nunberg
- Montana Biotechnology Center, The University of Montana, Missoula, MT 59812, United States
| | - Lihong Zhang
- Department of Pathology, The University of Texas Medical Branch, Galveston, TX 77555, United States
| | - Birte Kalveram
- Department of Pathology, The University of Texas Medical Branch, Galveston, TX 77555, United States
| | - Alexander N Freiberg
- Department of Pathology, The University of Texas Medical Branch, Galveston, TX 77555, United States; Center for Biodefense and Emerging Infectious Diseases, The University of Texas Medical Branch, Galveston, TX 77555, United States
| | - Dale L Boger
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, United States; The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, United States
| | - Greg Henkel
- Arisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego, CA 92054, United States
| | - Ken McCormack
- Arisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego, CA 92054, United States.
| |
Collapse
|
4
|
Li R, Xue L, Zhu T, Jiang Q, Cui X, Yan Z, McGee D, Wang J, Gantla VR, Pickens JC, McGrath D, Chucholowski A, Morris SW, Webb TR. Design and Synthesis of 5-Aryl-pyridone-carboxamides as Inhibitors of Anaplastic Lymphoma Kinase. J Med Chem 2006; 49:1006-15. [PMID: 16451066 DOI: 10.1021/jm050824x] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Anaplastic lymphoma kinase (ALK) is a promising new target for therapy of certain cancers such as anaplastic large-cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). We have identified a series of novel pyridones as kinase inhibitors of ALK by application of a stepwise process involving in vitro screening of a novel targeted library followed by iterative template modification based on medicinal chemistry insights and computational ranking of virtual libraries. Using this process, we discovered ALK-selective inhibitors with improved potency and selectivity. Herein the details of the design process and synthesis of these novel pyridones, along with their enzymatic and cell-based activity, are discussed.
Collapse
Affiliation(s)
- Rongshi Li
- ChemBridge Research Laboratories and ChemBridge Corporation, 16981 Via Tazon, Suites K and G, San Diego, CA 92127, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|